Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Breast cancer, early stage

164MO - Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results


18 Sep 2020


Mini Oral - Breast cancer, early stage


Tumour Site

Breast Cancer


Isabel Grote


Annals of Oncology (2020) 31 (suppl_4): S303-S339. 10.1016/annonc/annonc267


I. Grote1, S. Bartels2, L. Kandt2, L. Bollmann2, H. Christgen2, M. Gronewold2, O. Gluz3, U. Nitz3, S. Kümmel4, M. Braun5, B. Aktas6, E. Grischke7, C. Schumacher8, K. Lüdtke-Heckenkamp9, R. Kates10, R. Wuerstlein11, M. Gräser10, N. Harbeck11, M. Christgen2, H. Kreipe2

Author affiliations

  • 1 Institute Of Pathology, Hannover Medical School, 30623 - Hannover/DE
  • 2 Institute Of Pathology, Hannover Medical School, 30625 - Hannover/DE
  • 3 Breast Center Niederrhein, Evangelical Hospital Johanniter Bethesda, Moenchengladbach/DE
  • 4 Breast Unit, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 5 Abteilung Für Senologie, Klinikum Rotkreuz München, Munich/DE
  • 6 Gynecology And Obstetrics, University of Essen, Essen/DE
  • 7 Dept. Für Frauengesundheit, Universitätsklinikum Tübingen, 72072 - Tuebingen/DE
  • 8 Brustzentrum Köln-hohenlind, St. Elisabeth-Krankenhaus, Cologne/DE
  • 9 Niels-stensen-clinics, Franziskus-Hospital Harderberg, Osnabrück/DE
  • 10 Wsg, West German Study Group, Moenchengladbach/DE
  • 11 Ob&gyn, Brustzentrum der Universitaet Muenchen (LMU), Munich/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 164MO


Adjuvant endocrine therapy is a cornerstone in the treatment of hormone receptor (HR)-positive/HER2-negative breast cancer (BC). Neoadjuvant endocrine induction therapy (EIT) suppresses tumor cell proliferation and provides a clinically applicable read-out system for endocrine responsiveness. In a proof-of-principle study, we hypothesized, that incomplete growth suppression following to EIT is associated with genetic alterations in endocrine resistance genes.


Genetic alterations in candidate endocrine resistance genes (ARID1A, CCND1, ERBB2, ESR1, FGFR1, PAK1, and TP53) [1] were determined by next generation sequencing (NGS) and/or digital PCR (dPCR) in n=622 early BC cases treated with EIT in the West German Study Group (WSG) ADAPT trial (NCT0177920). Further, PIK3CA mutation status was determined because of its potential as target to selective inhibition treatment. Significance of association between distinct genetic alterations and incomplete growth suppression (post-EIT Ki67 <10%, versus 10-19%, 20-34%, ≥35%; provisional criteria for this translational research project) was determined with Chi square test for trends.


A total of n=351/622 (56.4%) BC cases harbored genetic alterations in at least one candidate gene. ARID1A, ERBB2, ESR1, PIK3CA, and TP53 gene mutations were affected in 5.3%, 2.9%, 0.6%, 43.3% and 9.0% of BC cases, respectively. CCND1, FGFR1, and PAK1 copy number gains were detected in 16.1%, 3.0% and 2.5% of tested patient samples. Of these candidate genes tested, only mutation of TP53 was significantly associated with incomplete growth suppression following EIT (P<0.0001). Mutation of TP53 was also associated with incomplete growth suppression in patient subsets treated with either tamoxifen or aromatase inhibitors for EIT (P=0.0005 each).


Our findings indicate that mutations associated with endocrine resistance and metastatic breast cancer [1], are enriched in short term endocrine treated primary luminal breast cancers with impaired Ki67 response. Ki67 response towards neoadjuvant endocrine treatment appears to reflect the genetic risk in breast cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

West German Study Group.


The study was supported by a grant from the Deutsche Krebshilfe to SB, MC, and HK (Grant Number 70112954).


S. Kümmel: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Genomic Health; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Celgene; Honoraria (self), Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Somatex; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: PFM; Honoraria (self), Advisory/Consultancy: Medical; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sonoscape; Leadership role, Shareholder/Stockholder/Stock options: WSG; Leadership role: AGO. M. Braun: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Celgene; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Exact Sciences; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Medac; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Teva. R. Wuerstlein: Honoraria (self): Agendia; Honoraria (self): Amgen; Honoraria (self): Aristo; Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Carl Zeiss; Honoraria (self): Celgene; Honoraria (self): Clinsol; Honoraria (self): Daiichi Sankyo; Honoraria (self): Eisai; Honoraria (self): Genomic Health; Honoraria (self): Glaxo Smith Kline; Honoraria (self): Hexal; Honoraria (self): Lilly; Honoraria (self): Medstrom Medical; Honoraria (self): MSD; Honoraria (self): Mundipharma; Honoraria (self): Nanostring; Honoraria (self): Novartis; Honoraria (self): Odonate; Honoraria (self): Paxman; Honoraria (self): Palleos; Honoraria (self): Pfizer; Honoraria (self): Pierre Fabre; Honoraria (self): PumaBiotechnology; Honoraria (self): Riemser; Honoraria (self): Roche; Honoraria (self): Sandoz/Hexal; Honoraria (self): Seattle Genetics; Honoraria (self): Tesaro Bio. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.